Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Jan 16, 2024--
Source: eagletribune.com
Historical Control News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Historical Control. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Historical Control Today - Breaking & Trending Today
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A...
Source: marketscreener.com
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proli
ADX-2191 Statistically Superior to Historical Control for Primary Endpoint of Prevention of Retinal Detachment (P=0.024)Numerical Superiority of ADX-2191 over Routine Surgical Care Achieved for Majority of Secondary, Exploratory, and Safety EndpointsADX-2191 Observed to be Well Tolerated with No Safety Concerns Note...
Source: pharmiweb.com
Margin Marking of Polyps Before EMR Cuts Recurrence: Study
An expert unaffiliated with the single-center analysis questions whether the margin-marking technique is truly better than current standard of care.
Source: medscape.com